Clinical Trials Sponsored by Novo Nordisk

Total 2904 results

Novo Nordisk A/S

Recruiting

A Study to See How Safe a New Medicine (NNC6022-0001) is in Healthy People

Healthy Volunteers | Cardiometabolic Diseases

Netherlands
Novo Nordisk A/S

Recruiting

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise (REIMAGINE 1)

Type 2 Diabetes

United States, Serbia, Italy, Poland, China, Hungary, Saudi Arabia
Novo Nordisk A/S

Not yet recruiting

Special Use - Results Surveillance on Long-term Use With Wegovy®

Obesity

Japan
Novo Nordisk A/S

Recruiting

A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis

Transthyretin Amyloid Cardiomyopathy (ATTR CM)

United States, Netherlands, Germany, Canada, Czechia, France, Italy, Portugal, Spain
Novo Nordisk A/S

Recruiting

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

Type 2 Diabetes

United States, Taiwan, Hungary, Australia, Germany, India, Canada, Spain, Czechia, Argentina, Poland, Colombia, South Africa, France, Greece, Romania
Novo Nordisk A/S

Not yet recruiting

A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation (ATHENA)

Heart Failure | Systemic Inflammation

United States, India, Czechia, Australia, Turkey, Canada, Portugal, France, United Kingdom, Malaysia, Spain, Germany, Greece, Poland, Bulgaria, Argentina
Novo Nordisk A/S

Recruiting

A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

Obesity | Type 2 Diabetes | Chronic Kidney Disease

United States, Spain, Thailand, India, France, Poland, Canada, Japan, Greece, Hungary, Argentina, Brazil, Slovakia
Novo Nordisk A/S

Recruiting

A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

Obesity

United States
Novo Nordisk A/S

Not yet recruiting

A Research Study in Italy to Understand How the Dose Check App Used With Xultophy® Works in the Treatment of People Living With Type 2 Diabetes

Diabetes Mellitus, Type 2

Italy
Novo Nordisk A/S

Recruiting

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III

Healthy Participants

Canada
Novo Nordisk A/S

Recruiting

Investigation of Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-6856 in Healthy Participants, Including a Subset of Healthy Japanese Participants

Healthy Participants

Germany
Novo Nordisk A/S

Recruiting

A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor (REIMAGINE 2)

Type 2 Diabetes Mellitus

Korea, Republic of, United States, Serbia, Hungary, Spain, China, Australia, Finland, United Kingdom, Italy, Denmark, Canada, Taiwan, Germany, Sweden, South Africa, India, Poland, Argentina, Brazil, Bulgaria, Japan, Mexico, Turkey, Greece, Colomb... and more
Novo Nordisk A/S

Recruiting

A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range (STEP12)

Obesity | Overweight

China, Taiwan
Novo Nordisk A/S

Recruiting

A Study to Look at How Safe a New Medicine (NNC0491-6075) is in Healthy People and in Participants With High Levels of Fat in the Blood

Healthy Volunteers | Dyslipidaemia

United States
Novo Nordisk A/S

Recruiting

A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight (STEP Young)

Obesity

Belgium, United Kingdom, Denmark, United States, Sweden, Portugal, Austria, Germany, Israel, Mexico
Novo Nordisk A/S

Recruiting

Research Study Investigating How Well NDec Works in People With Sickle Cell Disease (ASCENT1)

Sickle Cell Disease

Spain, United States, United Kingdom, Canada, Italy, India, Turkey, Greece, South Africa, France, Lebanon
Novo Nordisk A/S

Recruiting

A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow (REAL 8)

SGA, Turner Syndrome, Noonan Syndrome, ISS

Belgium, Korea, Republic of, United States, Ireland, Malaysia, United Kingdom, Finland, France, Netherlands, Italy, Thailand, China, Japan, Portugal, Israel, Brazil, Greece, India, Mexico, Bulgaria, Serbia, Lithuania, Austria, Canada, C... and more
Novo Nordisk A/S

Recruiting

A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors (Explorer10)

Haemophilia A and B With and Without Inhibitors

United States, Spain, Italy, Estonia, Thailand, Canada, India, Malaysia, United Kingdom, Turkey, South Africa, Lebanon, Bosnia and Herzegovina, Bulgaria, France, Greece, Japan, Lithuania, Norway, Poland, Romania, Russian Federation, Swede... and more
Novo Nordisk A/S

Recruiting

A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors

Haemophilia A With Inhibitors | Haemophilia A

United States, Korea, Republic of, France, Spain, Romania, Canada, Taiwan, China, Lithuania, Netherlands, India, South Africa, Russian Federation, Austria, Belgium, Czechia, Denmark, Germany, Ireland, Italy, Japan, Latvia, Malaysia, M... and more
Novo Nordisk A/S

Recruiting

Investigating Efficacy and Safety of Once-weekly NNC0195-0092 (Somapacitan) Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency

Growth Hormone Disorder | Growth Hormone Deficiency in Children

United States, India, Japan, Israel, Austria, Belgium, Brazil, France, Slovenia, Sweden, Turkey, Germany, Ukraine
Novo Nordisk A/S

Active, not recruiting

A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight

Obesity | Diabetes Mellitus, Type 2

United States, Canada, Hungary, Portugal, Slovakia, South Africa, Poland, Bulgaria
Novo Nordisk A/S

Active, not recruiting

Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

Non-alcoholic Steatohepatitis

Spain, Denmark, Taiwan, Korea, Republic of, Australia, Canada, India, Singapore, United States, Turkey, Poland, Italy, Belgium, Puerto Rico, United Kingdom, Malaysia, Germany, Portugal, Bulgaria, Czechia, France, Greece, Japan, Russian...
Novo Nordisk A/S

Active, not recruiting

A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight (REDEFINE 2)

Obesity | Overweight | Type 2 Diabetes Mellitus

United States, India, Poland, Malaysia, United Kingdom, Japan, Thailand, Germany, Austria, Canada, Hungary, Ireland, Puerto Rico
Novo Nordisk A/S

Enrolling by invitation

A Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Nephrologists

Systemic Inflammation | Chronic Kidney Disease (CKD) | Atherosclerotic Cardiovascular Disease (ASCVD)

United States
Novo Nordisk A/S

Enrolling by invitation

A Research Study in Saudi Arabia to Understand How the Dose Check App Used With Tresiba Treatment Helps to Control Blood Sugar Level (DEAL-2)

Diabetes Mellitus, Type 2

Saudi Arabia
Novo Nordisk A/S

Active, not recruiting

A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes (STRIDE)

Diabetes Mellitus, Type 2 | Peripheral Arterial Disease

Spain, Taiwan, China, India, United States, Canada, Thailand, Austria, Malaysia, Germany, Poland, Japan, Czechia, Greece, Belgium, Denmark, Hungary, Latvia, Norway, Sweden
Novo Nordisk A/S

Enrolling by invitation

Levels of Inflammation in People With Cardiovascular Disease (POSEIDON) (POSEIDON)

Heart Failure | Chronic Kidney Disease | Cardiovascular Risk

Korea, Republic of, China, United States, Argentina, Germany, Canada, Poland, Brazil
Novo Nordisk A/S

Completed

A Research Study Looking at Long-term Blood Sugar Control in People With Type 2 Diabetes Being Treated With Xultophy® in a Real-world Setting in Italy

Diabetes Mellitus, Type 2

Italy
Novo Nordisk A/S

Active, not recruiting

A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes in India (PIONEER REAL)

Diabetes Mellitus, Type 2

India
Novo Nordisk A/S

Active, not recruiting

DOORS: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Change From Dipeptidyl Peptidase-4 Inhibitor (DPP4i) Treatment to Oral Semaglutide in Italy (DOORS)

Diabetes Mellitus, Type 2

Italy
Novo Nordisk A/S

Completed

Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

China
Novo Nordisk A/S

Active, not recruiting

A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis

Transthyretin Amyloid Cardiomyopathy (ATTR CM)

United States, Netherlands, Spain, Portugal, Canada, Czechia, France, Germany, Italy, Japan
Novo Nordisk A/S

Completed

Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1) (OASIS 1)

Obesity | Overweight

Germany, Denmark, Canada, United States, Russian Federation, Finland, Poland, France, Japan
Novo Nordisk A/S

Enrolling by invitation

Influence of Adherence to Growth Hormone Therapy (GHT) With Norditropin® on Near Final Height in Patients With Growth Hormone Deficiency (GHD) and Born Small for Gestational Age (SGA)

Growth Hormone Deficiency in Children | Born Small for Gestational Age

Germany
Novo Nordisk A/S

Completed

A Research Study of How Different Doses of a New Medicine NNC0148-0287 C (Insulin 287) Work on the Blood Sugar in People With Type 1 Diabetes When it is Taken Once a Week

Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations

Non-alcoholic Steatohepatitis

Canada
Novo Nordisk A/S

Completed

Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients

Growth Hormone Disorder | Adult Growth Hormone Deficiency

France
Novo Nordisk A/S

Withdrawn

Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes

Diabetes Mellitus, Type 2

Thailand, Malaysia, Poland, India, Hungary, Mexico, Brazil, United States, Croatia, Romania, Bulgaria, Greece, Serbia
Novo Nordisk A/S

Completed

A Research Study to See How Much Semaglutide and SNAC is in the Milk of Healthy, Breastfeeding Women Taking Semaglutide Tablets

Diabetes Mellitus, Type 2

United States
Novo Nordisk A/S

Completed

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2) (COMBINE 2)

Diabetes Mellitus, Type 2

United States, China, Taiwan, Canada, Switzerland, Japan, Brazil, Russian Federation, Hungary, Greece, France, Israel, Sweden, Slovakia
Novo Nordisk A/S

Completed

A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease

Atherosclerotic Cardiovascular Disease

Germany, Poland, United States, Netherlands, Japan, Greece, Belgium
Novo Nordisk A/S

Enrolling by invitation

Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol

Haemophilia A

Denmark
Novo Nordisk A/S

Enrolling by invitation

A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN

Haemophilia B

Canada, United Kingdom, Czechia, Germany, Greece, Austria, Belgium, Croatia, Denmark, Finland, Norway, Portugal
Novo Nordisk A/S

Completed

A Research Study Looking Into Blood Levels of Three Different Formulations of the Study Medicine Ziltivekimab

Healthy Participants

Hungary, Netherlands
Novo Nordisk A/S

Enrolling by invitation

An Observational Study of Patients With Moderate Parkinson's Disease (TRANSCEND 1)

Parkinson Disease

United States, Japan, Sweden, United Kingdom
Novo Nordisk A/S

Completed

A Study to Understand the Distribution of Obesity Classes and Obesity Related Diseases in People With Obesity Across Countries in Czech Republic, Hungary and Poland (ExplorEUEast)

Obesity

Poland, Czechia, Hungary
Novo Nordisk A/S

Completed

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (PIONEER REAL)

Diabetes Mellitus, Type 2

Netherlands
Novo Nordisk A/S

Completed

O-SEMA-Fast: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Plan to Fast During Ramadan in the United Arab Emirates, Saudi Arabia, and Kuwait (O-SEMA-Fast)

Diabetes Mellitus, Type 2

United Arab Emirates, Kuwait, Saudi Arabia
Novo Nordisk A/S

Completed

A Clinical Study to Compare the Efficacy and Safety of a Novel Medicine (NNC0268-0965) With Insulin Glargine

Diabetes Mellitus, Type 2

Germany
Novo Nordisk A/S

Completed

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Sweden, as Part of Local Clinical Practice (PIONEER REAL)

Diabetes Mellitus, Type 2

Sweden

Clinical Trials Sponsored by Novo Nordisk

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations